According to Satya Nadella on Twitter, Microsoft Research detailed GigaTIME, a multimodal AI system that generates virtual populations to model the tumor microenvironment at scale, enabling faster in silico hypothesis testing for oncology R&D; as reported by Microsoft Research Blog, GigaTIME integrates histopathology, genomics, and clinical data to simulate cell–cell interactions and treatment responses, showing improved prediction fidelity versus single‑modal baselines and reducing simulation runtime from days to hours (source: Microsoft Research Blog). According to Microsoft Research Blog, the platform supports population‑level counterfactual analyses and cohort stratification for trial design, creating potential business value for pharma by prioritizing targets, optimizing dosing, and de‑risking early-stage studies with synthetic cohorts; as reported by Microsoft Research Blog, benchmarking on multi-cancer datasets demonstrated better generalization to out‑of‑distribution cohorts and more stable effect-size estimates, indicating utility for precision oncology workflows.